- Home
- IIIV vs PROK Comparison
IIIV vs PROK Comparison
Compare IIIV & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IIIV | PROK |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.2M | 416.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IIIV | PROK |
|---|---|---|
| Price | $20.75 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $33.20 | $7.40 |
| AVG Volume (30 Days) | 464.8K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | $263.44 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $18.47 | $1.53 |
| 52 Week High | $33.97 | $3.55 |
Technical Indicators
Market Signals| Indicator | IIIV | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 42.00 |
| Support Level | $20.31 | N/A |
| Resistance Level | $21.27 | $2.59 |
| Average True Range (ATR) | 0.92 | 0.15 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 33.38 | 12.86 |
Price Performance
Historical ComparisonAbout IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.